Effect of Ivermectin in treatment of COVID-19

Phase 3

Recruiting

• Conditions: COVID-19 disease.; COVID-19, virus not identified; U07.2

• Registration Number: IRCT20200506047323N6
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Age =20 years old
Weight =35 kg
Positive polymerase chain reaction (PCR) test for COVID-19
Non-hospitalized mild as well as hospitalized moderate patients
Signed informed consent voluntarily and knowingly

Exclusion Criteria

Underlying diseases (AIDS, asthma, severe liver and kidney disease)
History of Loiasis
History of drug allergy to Ivermectin
Use of anticoagulants (e.g. warfarin) and ACE inhibitors (e.g. captopril)
Pregnancy or breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ength of hospital stay. Timepoint: Until discharge date. Method of measurement: Questionnaire.;Need for ICU. Timepoint: Until discharge date. Method of measurement: Questionnaire.;Need for mechanical ventilation. Timepoint: Until discharge date. Method of measurement: Questionnaire.

Secondary Outcome Measures

Name	Time	Method
Incidence of serious adverse reactions. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.